14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
AVDL vs GBIO
Tradestie Institutional Equity Comparison Engine · Market Close Feb 11, 2026
AVDL vs GBIO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AVDL Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 7–2 Matrix Metrics)
AVDL Overall Winner
6-Pillar Tally: AVDL 3 – 1 GBIO (2 Tie)
Matrix Metrics: AVDL 7 – 2 GBIO
As of Feb 11, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Generation Bio Co. (GBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas GBIO carries 58.8/100 (HOLD) at $5.34 (7.9x Forward P/E, -2020.0% operating margin).
AVDL
NASDAQ
Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
Market Cap
$2.1B
TTM Revenue
$249M
Forward P/E
28.8x
Beta / 30D Vol
0.14β · 2% Vol
Unified Composite Score
62.9 / 100
BUY
Tech 75.0
Fund 60.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
GBIO
NASDAQ
Generation Bio Co. Common Stock
Pharmaceutical Preparations
Market Cap
$38.7M
TTM Revenue
$15M
Forward P/E
7.9x
Beta / 30D Vol
0.80β · 26% Vol
Unified Composite Score
58.8 / 100
HOLD
Tech 40.0
Fund 47.0
Flow 50.0
Mom 53.9
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 39.7 · SMA20: $5.61 · SMA50: $5.49
6-Pillar Scorecard Institutional Category Breakdown (AVDL 3 – 1 GBIO)
Columns: Metric · AVDL · GBIO
1. Valuation Multiples
GBIO
Forward P/E
28.8x
7.9x
Trailing P/E
16.8x
7.9x
PEG Ratio
0.07x
N/M
EV / Revenue
8.5x
2.5x
2. Growth & Scale
AVDL
Revenue Growth (YoY)
+54.9%
-78.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$249M
$15M
Market Cap
$2.1B
$38.7M
3. Profitability & Quality
AVDL
Gross Margin
94.9%
N/A
Operating Margin
2.5%
-2020.0%
Net Profit Margin
-0.1%
0.0%
Return on Equity (ROE)
-0.3%
-80.8%
4. Balance Sheet & Cash Flow
AVDL
Cash Generation (TTM)
$2.7M EBITDA
-$76M EBITDA
Cash Flow Margin
1.1% EBITDA Mgn
N/A
Net Cash / Leverage
$1.01 Book/Sh · -0.3% ROE
$7.51 Book/Sh · -80.8% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
2.4% (<1st %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Drug Manufacturers - Specialty & Generic Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: AVDL (7) vs GBIO (2)
Institutional Metric
AVDL
GBIO
Criterion
Row Edge
Market Capitalization
Scale
$2.1B
$38.7M
Larger Scale
AVDL
Trailing P/E Ratio
Valuation
16.8x
7.9x
Lower Multiple
GBIO
Forward P/E Ratio
Valuation
28.8x
7.9x
Lower Multiple
GBIO
Revenue Growth (YoY)
Growth
+54.9%
-78.9%
Higher Growth
AVDL
Operating Margin (TTM)
Profitability
2.5%
-2020.0%
Higher Margin
AVDL
Net Profit Margin
Profitability
-0.1%
0.0%
Higher Margin
Tie
Return on Equity (ROE)
Capital Efficiency
-0.3%
-80.8%
Higher ROE
AVDL
52-Week Range Position
Momentum
89% ($6–$24)
62% ($0–$8)
Stronger Trend
AVDL
Beta / 30D Volatility
Risk Regime
0.14β · 2% Vol
0.80β · 26% Vol
Lower Realized Risk
AVDL
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY)
58.8 / 100 (HOLD)
Higher Composite
AVDL
Trailing 12M Revenue (USD)
Operating Scale
$249M
$15M
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.9%
N/A
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.07x PEG · 8.5x EV/Rev
N/M PEG · 2.5x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE)
-$76M EBITDA ($7.51 Book/Sh · -80.8% ROE)
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
AVDL +3.26 pp
AVDL:
+0.88%
·
GBIO:
-2.38%
3M Horizon
AVDL +11.51 pp
AVDL:
+14.4%
·
GBIO:
+2.89%
6M Horizon
AVDL +41.58 pp
AVDL:
+70.25%
·
GBIO:
+28.67%
1Y Horizon
AVDL +162.32 pp
AVDL:
+138.61%
·
GBIO:
-23.71%
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Split-Invariant USD Revenue & Operating Margin (%)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs GBIO. Trailing 12-month operating profitability (AVDL 2.5% vs GBIO -2020.0%) and valuation multiples (AVDL 28.8x vs GBIO 7.9x Forward P/E) are benchmarked directly in Pillar 4 below.
AVDL ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $249M
Gross Margin 94.9%
Op. Margin 2.5%
ROE / Fwd P/E -0.3% · 28.8x
GBIO ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $15M
Gross Margin N/A
Op. Margin -2020.0%
ROE / Fwd P/E -80.8% · 7.9x
AVDL
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
2.4%
IV Percentile
<1st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
GBIO
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
AVDL Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
GBIO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $38.7M market capitalization and -2020.0% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ AVDL vs GBIO Key Questions & Quantitative Answers
Is AVDL or GBIO a better stock to buy right now?
As of Feb 11, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Generation Bio Co. (GBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas GBIO carries 58.8/100 (HOLD) at $5.34 (7.9x Forward P/E, -2020.0% operating margin). Technically, AVDL sits in a Markup phase (RSI 62.3, UNCLASSIFIED options structure) and GBIO sits in a Neutral phase (RSI 39.7, UNCLASSIFIED options structure).
Does AVDL or GBIO have stronger revenue and earnings growth?
AVDL leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with GBIO at -78.9% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (N/A gross margin, -2020.0% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $15M for GBIO. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GBIO.
Is AVDL or GBIO cheaper on valuation?
GBIO screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas GBIO trades at 7.9x Forward P/E, 7.9x Trailing P/E, N/M PEG, and 2.5x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus GBIO (-80.8% ROE) capital efficiency.
How is options market volatility positioned on AVDL vs GBIO?
In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, GBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 26% Vol realized risk).
Avadel Pharmaceuticals plc Ordinary Share (AVDL) Research Suite
Generation Bio Co. Common Stock (GBIO) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Feb 11, 2026. For educational research only; not investment advice.